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Introduction
Dysregulated lipid metabolism and inflammation are key contributors to the development of  multiple dis-
eases of  aging, including the ocular neurodegenerative disease, age-related macular degeneration (AMD), 
a leading cause of  blindness in the elderly in developed nations, which affects over 130 million people in 
toto (1, 2). A hallmark of  the “early” dry clinical subtype of  AMD is choriocapillary dropout (3) as well 
as accumulation of  lipid- and protein-rich deposits, known as drusen, below the retinal pigment epithelial 
(RPE) layer, support cells to the retina (4, 5). Although the pathogenesis of  early dry AMD remains to be 
fully understood, an array of  risk factors have been identified, implicating disease-associated signaling path-
ways, most notably, age, along with environmental (e.g., smoking), and genetic factors (e.g., genes associated 
with inflammatory, complement, and lipid-regulating pathways) (6–9). In spite of  the wealth of  accepted 
knowledge regarding potential risk factors, treatment options remain tenuous for patients suffering from the 
“early” dry form of  AMD. Therefore, there is a considerable need not only to identify critical signaling path-
ways that drive the initiation and progression of  AMD but also to develop appropriate animal models that 
could then be used as a platform to test potential therapies and further discover disease-regulating pathways.
Nuclear receptors are the largest family of  transcription factors in the human genome and facilitate 
the expression of  a variety of  genes important in maintaining cellular homeostasis during development 
Effective treatments and animal models for the most prevalent neurodegenerative form of 
blindness in elderly people, called age-related macular degeneration (AMD), are lacking. Genome-
wide association studies have identified lipid metabolism and inflammation as AMD-associated 
pathogenic pathways. Given liver X receptors (LXRs), encoded by the nuclear receptor subfamily 
1 group H members 2 and 3 (NR1H3 and NR1H2), are master regulators of these pathways, herein 
we investigated the role of LXR in human and mouse eyes as a function of age and disease and 
tested the therapeutic potential of targeting LXR. We identified immunopositive LXR fragments 
in human extracellular early dry AMD lesions and a decrease in LXR expression within the retinal 
pigment epithelium (RPE) as a function of age. Aged mice lacking LXR presented with isoform-
dependent ocular pathologies. Specifically, loss of the Nr1h3 isoform resulted in pathobiologies 
aligned with AMD, supported by compromised visual function, accumulation of native and oxidized 
lipids in the outer retina, and upregulation of ocular inflammatory cytokines, while absence of 
Nr1h2 was associated with ocular lipoidal degeneration. LXR activation not only ameliorated lipid 
accumulation and oxidant-induced injury in RPE cells but also decreased ocular inflammatory 
markers and lipid deposition in a mouse model, thereby providing translational support for 
pursuing LXR-active pharmaceuticals as potential therapies for dry AMD.
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and aging (10, 11). Importantly, they play a regulatory role in diseases of  aging including Alzheimer’s 
disease (12, 13), cardiovascular disease (14), and cancer (15). Given the commonality between patho-
genic pathways regulated by nuclear receptors in age-related diseases and AMD, in an attempt to identi-
fy candidate receptors that may be important in disease initiation and progression, we previously devel-
oped a nuclear receptor atlas of  human RPE cells, cells vulnerable in AMD (16). The liver X receptor 
(LXR; nuclear receptor subfamily 1 group H, NR1H), emerged as a promising target, in light of  its role 
as a regulator of  cholesterol homeostasis (17, 18) and inflammation (18), 2 pathways modulated in 
AMD (19). Further justification for investigating the role of  LXR in the aging eye comes from genome-
wide association studies, which have found a correlation between single nucleotide polymorphisms in 
genes involved in cholesterol metabolism/transport and AMD, including member 1 of  human trans-
porter subfamily ATP binding cassette transporter (ABCA1), cholesteryl ester transfer protein, hepatic 
triglyceride lipase C, and lipoprotein lipase (9, 20, 21), known LXR target genes (22).
To test the hypothesis that the LXR signaling pathway regulates AMD pathology and may serve 
as a potential target for therapy, we interrogated the role of  the LXR pathway in ocular cells vulner-
able in AMD. We evaluated the expression of  LXR in human RPE cells derived from donor eyes as 
a function of  age, examined the distribution of  LXR in human donor eyes as a function of  disease, 
and compared LXR expression throughout compartments of  the ocular posterior pole. Activation of  
the receptor was further evaluated in vitro, under AMD-relevant stressed conditions with pharma-
cological LXR ligands. The ocular function and phenotype of  aged mice lacking the LXR isoforms 
(Nr1h3−/−, Nr1h2−/−, and Nr1h3−/− Nr1h2−/−) were catalogued and the therapeutic potential of  activating 
the LXR signaling pathway on the “AMD” phenotype, including extracellular lipid accumulation and 
inflammation in the back of  the mouse eye, was tested. We report a decrease in NR1H3 expression in 
human RPE cells as a function of  age and accumulation of  LXR immunopositive fragments within 
drusen of  dry AMD eyes, reinforcing vulnerability to AMD development through this pathway. We 
found that LXR-activating ligands are able to improve mitochondrial function and decrease lipid load 
in RPE cells following injury. Furthermore, we established that the absence of  LXR affects the visual 
function and ocular phenotype of  mice differentially, with the absence of  the Nr1h3 isoform resulting 
in the accumulation of  extracellular lipid- and protein-rich deposits, phenotypic features of  dry AMD, 
while the absence of  the Nr1h2 isoform also resulted in non-AMD phenotypes, namely stellate cataract 
formation and RPE-associated lipoidal degeneration. Detailed analysis of  mouse eyes lacking Nr1h3 
revealed a proinflammatory microenvironment, as evidenced by the accumulation of  immune cells in 
the outer retina and confirmed through analysis of  the cytokine profile of  the mouse RPE-choroid. 
Finally, LXR activation was able to reduce AMD-relevant pathogenic phenotypes, including posterior 
pole ocular inflammation and lipid deposition in mice expressing apoB100, a model for aging and 
early AMD-associated phenotypes (23, 24).
Our studies, collectively, highlight the importance of  the NR1H3 signaling pathway in the health of  
aged RPE cells and present a potentially novel mouse model for the dry AMD phenotype featuring lip-
id-rich sub-RPE deposits along with accumulation of  subretinal immune cells. This model may serve 
as a platform to test new therapies and identify additional therapeutic targets. Importantly, our results 
provide translational support for approaches including direct activation of  the LXR pathway, which 
is capable of  reducing AMD-associated pathologies and may be a therapeutic target for not only the 
early dry form of  AMD but also other ocular and nonocular diseases characterized by either abnormal 
lipid deposition or tissue immune cell infiltration.
Results
LXR expression in human RPE cells decreases as a function of  age. Given the critical role of  advanced age in 
the development of  AMD, we measured the relative expression of  NR1H3 (LXRA) and NR1Η2 (LXRB) in 
human RPE cells isolated from donor tissue as a function of  age (Figure 1, Supplemental Figure 1, and 
Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.131928DS1). A significant negative correlation was found between relative NR1H3 and NR1H2 
expression levels and age (Figure 1A and Supplemental Figure 1A). This negative correlation remained 
significant for NR1H3 expression, not NR1H2, in the “at risk for AMD” age range of  60–94 years, sug-
gesting a steady decline in NR1H3 but a plateau in NR1H2 expression in human RPE cells (Figure 1B 
and Supplemental Figure 1B). In a smaller cohort of  RPE tissue from middle- to advanced-age donors, 
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expression of  LXR target genes ABCA1 (n = 12) and of  apolipoprotein E (APOE) (n = 15) were found to 
increase with age (Supplemental Figure 2, A and B). The purity of  freshly isolated RPE cells from human 
donors was assessed by measuring the expression of  bestrophin-1 (BEST1) and RPE-specific protein 65/
retinoid isomerohydrolase RPE65 (RPE65) in freshly isolated RPE, retina, and choroid from corresponding 
donors. RPE samples (n = 23) were found to have a 2.13 × 102–fold to 4.52 × 105–fold higher expression 
of  BEST1 and 4.98 × 102 –fold to 2.15 × 104–fold higher expression of  RPE65, relative to ARPE19 cells. 
Additionally, the expression levels of  BEST1 and RPE65 in retina and choroid were negligible (0.01- to 
0.3-fold change for BEST1 and 0.009- to 0.2-fold change for RPE65) as compared with the RPE, reflecting 
the purity of  the samples. Importantly, all the components of  the LXR pathway were expressed in freshly 
isolated tissue and cultured cells (Figure 1C). We next evaluated the localization of  NR1H3 and ΝR1Η2 
Figure 1. NR1H3 expression in RPE declines with age. (A) Expression of NR1H3 in RPE cells isolated postmortem from donors, 18–94 years old; fold change 
relative to ARPE19; n = 31. Pearson’s R2 was calculated, P < 0.0001. (B) Expression of NR1H3 in RPE cells isolated postmortem from donors, 60–94 years 
old; fold change relative to ARPE19, n = 25. Pearson’s R2 was calculated; P = 0.018. (C) Agarose gel image of genomic DNA amplification products of NR1H3, 
NR1H2, and their obligate binding partners retinoid X receptors A and B (RXRA and RXRB) in retina, freshly isolated human RPE cells (fRPE), ARPE19 cells, 
primary human RPE cells (hRPE), human choroid, and RF/6A cells. β-Actin (ACTB) was used a loading control. Representative images of NR1H3 (12HCLC) 
immunohistochemical (IHC) staining (dark gray) in retina/RPE/choroid complex from non-AMD (D and E; arrows point to a cone and RPE cells) and AMD (G 
and H) donors. Arrowheads point to dark gray NR1H3 staining within drusen. Inset: IgG control. Scale bars: 50 μm (D), 25 μm (E). (F and I) NR1H3 immuno-
fluorescence (IF) staining in non-AMD and AMD donors. Arrowheads point to NR1H3 staining, red. Scale bar: 25 μm (F). NR1H2 IHC staining in retina/RPE/
choroid complex from non-AMD (J and K) and AMD (M and N) donors (arrowheads point to dark gray NR1H2 staining within drusen). (L and O) NR1H2 IF 
staining in non-AMD and AMD donors (arrowheads point to NR1H2 staining within drusen, green). Total number of eyes probed with antibodies (n = 2–10 
from age-matched non-AMD and AMD donors, respectively). IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer 
nuclear layer; OS, outer segments; RPE, retinal pigment epithelial cells.
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protein in retinal cross sections from AMD and age-matched unaffected “normal” donor eyes via IHC. In 
sections from unaffected donors, NR1H3 immunoreactivity was observed in RPE cells and select cones 
(Figure 1, D–F), while NR1H2 immunoreactivity was also present throughout the inner retina (Figure 1, 
J–L). In AMD donor sections, NR1H3 immunoreactivity was less evident in the RPE cell layers (Figure 
1, G–I) but still present, though at lower levels, and NR1H3-immunopositive fragments were seen in large 
drusen in 6 out of  9 donor tissues (Figure 1 and Supplemental Figure 3), in addition to cone cells, as shown 
by red/green opsin staining (Supplemental Figure 4). This staining pattern was supported using a different 
primary antibody against NR1H3 (Supplemental Figure 4). NR1H2 immunoreactivity in drusen was also 
abundant in addition to diffuse staining within the neural retina of  AMD eyes, reflecting the ubiquitous 
nature of  this isoform (Figure 1, M–O).
The LXR pathway is biologically active in AMD-vulnerable cells. NR1H3 and NR1H2 activities were examined 
in hRPE cells and the macaque-derived RF/6A choroidal endothelial cell (CEC) lines. Receptor transcription-
al activity was assessed by measuring the binding of  the receptor-ligand complex to the gene response element 
using a luciferase reporter assay. Ligand activation by GW3965 and TO901317, 2 nonsteroidal LXR-active 
pharmaceuticals (Supplemental Table 3), significantly increased LXR promoter activity in hRPE (GW3965, 
4-fold; TO901317, 2-fold; Figure 2A) and CEC (GW3965, 2.5-fold; TO901317, 5-fold; Figure 2D) lines. This 
induction was reversed following siRNA-induced knockdown of NR1H3 and NR1H2 expression. Conversely, 
LXR antagonist (GSK2033) treatment did not result in promoter binding. Ligand activation by GW3965 and 
TO901317 significantly induced expression of  LXR target genes, FASN and SREBF1 in both hRPE (from a 
93-year-old female; Figure 2, B and C) and CEC (Figure 2, E and F) lines. Similar induction patterns of  LXR 
target genes in response to agonists were observed in 2 additional primary RPE cell lines (from a 15- and 
Figure 2. The LXR pathway is biologically active in AMD-vulnerable cells. (A) LXR activity in hRPE cells transfected with DR-4 luciferase reporter and siC 
(control, nontargeting siRNA), siNR1H3, siNR1H2, or siNR1H3/NR1H2 and treated with LXR agonists GW3965 and TO901317 or antagonist GSK2033. DMSO was 
used as a vehicle control. n = 3. Mean ± SEM shown. *P < 0.05 relative to siC DMSO; #P < 0.05 relative to drug siC–treated cells. Two-way ANOVA and Tukey’s 
multiple comparisons. Expression of LXR target genes fatty acid synthase (FASN) (B) and sterol regulatory element-binding protein 1 (SREBF1) (C) in hRPE 
cells in response to treatment with LXR agonists GW3965 and TO901317 and antagonist GSK2033. n = 3. Mean ± SEM. *P < 0.05 relative to siC DMSO; #P < 
0.05 relative to drug siC–treated cells, 2-way ANOVA and Tukey’s multiple comparisons. (D) LXR activity in CECs transfected with DR-4 luciferase reporter and 
siC, siNR1H2, siNR1H2, or siNR1H3/NR1H2 cells and treated with LXR agonists GW3965 and TO901317 or antagonist GSK2033. DMSO was used as a vehicle 
control. n = 3. Mean ± SEM. *P < 0.05 relative to siC DMSO; #P < 0.05 relative to drug siC–treated cells. Two-way ANOVA and Tukey’s multiple comparisons. 
Expression of LXR target genes FASN (E) and SREBF1 (F) in CECs in response to treatment with LXR agonists GW3965 and TO901317 and antagonist GSK2033. 
n = 3. Mean ± SEM. *P < 0.05 relative to siC DMSO; #P < 0.05 relative to drug siC–treated cells, 2-way ANOVA and Tukey’s multiple comparisons.
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60-year-old). Collectively, these results demonstrate that components of  the LXR pathway are expressed, 
and LXR activity and target gene expression can be modulated through pharmacological drugs and siRNA, 
respectively, in ocular cells vulnerable to AMD. Furthermore, variation in the magnitude of  LXR induction 
and expression illustrates the differential nature and cell-specific effects of  these ligands.
LXR activation differentially ameliorates oxidant injury and lipid overload in a ligand-dependent manner in the 
eye. The retina is susceptible to oxidant injury culminating from inadequate neutralization of  generated 
reactive oxygen species (ROS). This high ROS load is a consequence of  the retina’s daily exposure to visible 
light, its high oxygen consumption, the daily phagocytosis of  photoreceptor outer segments, as well as its 
polyunsaturated fatty acid–rich environment (25). Human RPE cells were exposed to agents simulating 
oxidant injury (i.e., NaIO3, H2O2, and cigarette smoke extract, CSE), and lipid overload (i.e., palmitic 
acid, PA; and α-linolenic acid, α-LA; Supplemental Table 3). The effects of  LXR modulation in response 
to oxidant- and lipid-induced damage to the RPE cells were determined by evaluating the activity assay, 
mitochondrial membrane potential using the JC-1 assay, lipid buildup in the cells by AdipoRed assay, 
and cell viability by CellTiter-Blue assay. We found that the treatment with oxidant injury and lipids did 
not directly induce LXR activity in RPE cells (Supplemental Figure 5). A 24-hour pretreatment of  RPE 
cells with the LXR ligand TO901317 was able to prevent the compromise to the mitochondrial membrane 
potential in NaIO3-treated, H2O2-treated, and CSE-treated cells, whereas GW3965 pretreatment was able 
to block mitochondrial injury in lipid-treated cells (Figure 3A and Supplemental Figure 6). LXR antagonist 
GSK2033 pretreatment had no appreciable effect on the mitochondrial membrane potential. Additionally, 
we measured the neutral lipid content in RPE cells in response to oxidant injury and lipid overload and 
examined whether LXR pathway modulation could prevent the accumulation of  neutral lipids in RPE 
cells. Lipid treatments (PA and α-LA) induced a buildup of  neutral lipids within cells, which was ameliorat-
ed by pretreatment with GW3965 (Figure 3B). The agonist TO901317, and antagonist GSK2033, did not 
affect lipid accumulation in RPE cells in vitro. Finally, cell viability assessments confirmed that the drug 
pretreatments and injury treatments were sublethal for the course of  the assay (Figure 3C). These results 
revealed the therapeutic potential of  activating the LXR pathway to avert oxidant injury and lipid accumu-
lation in RPE cells. Importantly, the 2 LXR agonists tested appear to work via distinct pathways, as evident 
by their selective action in response to diverse injury agents.
Loss of  Nr1h3 in vivo compromises visual function. Given the role of  LXR in regulating lipid metabolism 
and inflammation, the 2 pathways associated with development of  AMD, and our observation that LXR 
expression in human RPE cells decreases with age, we examined the visual function of  aged LXR-knock-
out mice, after confirming that the absence of  LXR globally also affects LXR gene expression locally in 
the RPE-choroid (Supplemental Figure 7). Visual function was assessed by recording electroretinograms 
(ERGs) from 10- to 14-month-old Nr1h3–/– (n = 11), Nr1h2–/– (n = 11), Nr1h3–/– Nr1h2–/– (n = 2), and Nr1h3+/+ 
Nr1h2+/+ (WT, n = 15) controls. Evaluation of  the ERG recordings revealed a decline in scotopic a-wave 
Figure 3. LXR activation differentially ameliorates oxidant injury and lipid overload in a ligand-dependent manner. Human primary RPE cells from a 
93-year-old donor were pretreated with LXR agonists or antagonists followed by oxidant injury or lipid overload and the (A) effect of LXR activation on 
the mitochondrial membrane potential was measured by exposure to the JC-1 dye, in which the ratio of JC-1 monomers/aggregates was used as a measure 
of mitochondrial injury. (B) Intercellular lipid accumulation was quantified in AdipoRed assays. (C) Cell viability was measured using CellTiter-Blue. Drugs 
used included the LXR agonists GW3965 and TO901317 and antagonist GSK2033. DMSO and ethanol were used as vehicle controls. n = 3. Mean ± SEM 
shown. *P < 0.05 relative to vehicle control; #P < 0.05 relative to drug control, 2-way ANOVA and Tukey’s multiple comparisons.
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(approximately 41%), scotopic b-wave (approximately 26%), and photopic b-wave amplitudes (approxi-
mately 28%) of  Nr1h3–/– mice compared with WT controls (Figure 4, A–C), indicating that in the absence 
of  Nr1h3, visual function may be compromised at several levels, including the photoreceptors and retinal 
cells postsynaptic to photoreceptors. We also evaluated the visual function of  Nr1h3–/– mice as a function of  
age and observed an age-related decline in scotopic a-wave and b-wave amplitudes (4- to 5-month-olds com-
pared with 10- to 12-month-olds; Supplemental Figure 8), supporting a role for Nr1h3 in the maintenance 
of  retinal cell health. Upon further examination, gene-specific differences in the localization of  retinal cell 
markers for photoreceptors (Supplemental Figure 9, A and B) and Müller and bipolar cells (Supplemental 
Figure 9, C and D) were not seen, and no differences in retinal layer thicknesses were observed (Supplemen-
tal Figure 10). However, a significant decline (24.9%) in the c-wave amplitude in Nr1h3–/– mice compared 
with WT controls (Figure 4D) was observed, reflecting the contribution of  the RPE to the visual function 
decline observed in these mice (26). Although Nr1h2–/– mice did not display any gene-specific differences 
in visual function, the Nr1h3–/– Nr1h2–/– mice followed a similar trend to the Nr1h3–/– mice (Figure 4). 
Finally, no significant isoform-specific differences were seen in dark adaptation and a-wave flash sensitivity. 
Some LXR-dependent changes in the recovery kinetics for a-wave amplitude were seen but only at early 
time points (Figure 4, E and F).
Isoform-specific ocular pathologies indicate absence of  LXRα is associated with an early dry AMD phenotype. In 
vivo imaging allowed examination of  the morphology of  the fundus and OCT images from aged Nr1h3–/–, 
Nr1h2–/–, and Nr1h3–/– Nr1h2–/– and WT controls. Whereas the fundus and OCT images from the WT mice 
were not remarkable (Figure 5, A and B), the Nr1h3–/– mice exhibited hypopigmented regions in the fundus 
(Figure 5, C and D, and Supplemental Figure 11, A–H). Similarly, Nr1h3–/– Nr1h2–/– mouse fundus images 
presented with pigmentary changes in the fundus (Figure 5, G and H). Nr1h2–/– mice, in addition to retinal 
Figure 4. Loss of Nr1h3 in vivo compromises visual function. Averaged ERG responses from 10- to 14-month-old dark-adapted WT, Nr1h3–/–, Nr1h2–/–, 
and Nr1h3–/– Nr1h2–/– mice. Plots of (A) scotopic a-wave amplitudes, (B) scotopic b-wave amplitudes, and (C) photopic a-wave amplitudes as a 
function of flash intensity are shown. WT, n = 15; Nr1h3–/–, n = 11; Nr1h2–/–, n = 11; Nr1h3–/– Nr1h2–/–, n = 2. *P < 0.05, Nr1h3–/– relative to WT; #P < 0.05, 
Nr1h2–/– relative to WT. Mean ± SEM. Multiple t tests. (D) C-wave amplitudes. n = 4, Mean ± SEM shown. *P < 0.05; ns, not significant; 1-way ANOVA, 
Dunnett’s multiple-comparisons test. Dark adaptation ERG was performed and results were reported as (E) sensitivity as a function of time (WT: n = 
4, Nr1h3–/–: n = 4, Nr1h2–/: n = 4; mean ± SEM shown) and (F) ratio of a-wave amplitude (a wave)/prebleach a-wave amplitude (A wave max). WT, n = 
4; Nr1h3–/–, n = 4; Nr1h2–/–, n = 4. Mean ± SEM is shown.
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changes, developed stellate cataracts (Figure 5, E and F, and Supplemental Figure 11, I–L), resulting in 
cloudy fundus images. The overall architecture of  the inner retinas of  LXR-null mice was evaluated ex 
vivo in cross sections, and no gene-specific differences in the overall architecture and thickness of  the inner 
retinal layers were found (Nr1h3–/–, n = 5; Nr1h2–/–, n = 3; Nr1h3–/– Nr1h2–/–, n = 4; and WT, n = 4; Figure 5, 
I–L, and Supplemental Figure 10). High-magnification evaluation of  the outer retina of  LXR mice using 
conventional transmission electron microscopy (cTEM) allowed for detailed analysis of  the ultrastructure 
of  the RPE-choroid complex. Although eyes from WT mice exhibited normal RPE-choroid morphology 
with organized basal infoldings and apical processes of  the RPE (Figure 5, M and N), in Nr1h3–/– mice, 
continuous sub-RPE deposits were observed below disrupted basal infoldings, seen as amorphous, elec-
tron-dense material, interspersed with “streamers,” a phenotype typical of  early dry AMD (over 40% of  the 
length of  Bruch’s membrane, BrM; Figure 5, O and P, and Supplemental Figure 12). The RPE phenotype 
of  Nr1h2–/– mice had distinct pathologies, including accumulation of  large lipid droplets within the RPE, 
reminiscent of  lipoidal degeneration, which is not a characteristic of  AMD (Figure 5, Q and R, and refs. 
27, 28). Predictably, Nr1h3–/– Nr1h2–/– mice displayed both phenotypes, large lipid droplets within the RPE 
in combination with accumulation of  extracellular electron-dense sub-RPE deposits (Figure 5, S and T). 
Based on these morphological findings we conclude that in the eye the α-isoform of  LXR regulates extra-
cellular lipid deposition, an early phenotypic feature of  dry AMD, while the β-isoform is responsible for 
intracellular lipid accumulation as well as stellate cataract, an ocular pathology of  the anterior segment.
Figure 5. Pathology of Nr1h3–/– mice reveals isoform-specific differences. Micron IV–acquired in vivo images of 
the posterior poles of 10- to 14-month-old (A and B) WT (n = 4), (C and D) Nr1h3–/– (n = 5), (E and F) Nr1h2–/– (n = 3), 
and (G and H) Nr1h3–/– Nr1h2–/– (n = 4) mice. Black arrowheads point to hyporeflective spots in the fundus. Toluidine 
blue–stained images of plastic sections from (I) WT (n = 4), (J) Nr1h3–/– (n = 5), (K) Nr1h2–/– (n = 3), and (L) Nr1h3–/– 
Nr1h2–/– (n = 4) mice showed normal retinal morphology and no gene-specific differences at the level of the inner 
retina. Scale bar: 20 μM (I). Conventional electron micrographs of RPE/Bruch’s membrane/choroidal junction in 
(M and N) WT mice display normal RPE morphology, while (O and P) Nr1h3–/– mice illustrate continuous sub-RPE 
deposits (marked by red dotted line) and disorganized RPE basal infoldings. (Q and R) Nr1h2–/– mice develop sub-
RPE deposits (marked by red dotted line) along with large lipid droplets (red arrowheads) within the RPE, while (S 
and T) Nr1h3–/– Nr1h2–/– mice display a more severe form of both pathologies. Sub-RPE deposits, red dotted line; lipid 
droplets, red arrowheads. cTEM scale bar: 1 μm. CC, choriocapillaris; OS, outer segments; ONL, outer nuclear layer; 
OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer.
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Figure 6. NR1H3 regulates lipid deposition in the outer retina. Representative images from retina/RPE/choroid sections of 10- to 14-month-old (A) WT (n 
= 3), (B) Nr1h3–/– (n = 4), (C) Nr1h2–/– (n = 4), and (D) Nr1h3–/– Nr1h2–/– (n = 3) mice stained with Oil Red O to visualize neutral lipids are shown. Scale bar: 20 
μm. Retina/RPE/choroid sections from 10- to 14-month-old (E) WT (n = 3) (F) Nr1h3–/– (n = 4) mice were stained for APOE (red) and EO6 (green). Repre-
sentative images are shown. Scale bar: 20 μm. QFDE micrographs from 10- to 14-month-old (G and H) WT (n = 4) and (I, J, and L) Nr1h3–/– (n = 4) mice. In 
these micrographs, the fracture plan “hovers” between the RPE basal infoldings (BIs) and choriocapillaris (CC). (G) In the WT mouse, the BIs are located in 
the lower half and left side of the micrograph (BI, black border). The BI structure appears uniform and consistent. (I) In the Nr1h3–/– mouse, the BI region 
is located in the center of the micrograph and along the bottom edge (red border). Regions of the BI that have the unaffected structure (labeled BI, within 
black border), are predominantly adjacent to BrM, but most of the region in this micrograph shows a heavily disrupted BI (dBI). (H) Inset shows a higher 
magnification of a region that contains both healthy BI and BrM. (J) Inset shows the surface structure of the dBI and healthy BI. (K) Inset shows a high 
magnification of the dBI structure marked by the box in inset J. Scale bar: 4 μm (G and I), 1 μm (inset H and J), 250 nm (inset K). BrM, Bruch’s membrane; 
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Nr1h3 regulates lipid deposition in the outer retina. Accumulation of  neutral lipids with age in BrM and 
extracellular to the RPE has been correlated with drusen formation (29, 30). Given the reported role of  
LXR in regulating lipid metabolism, we stained cryosections from Nr1h3–/– (n = 4), Nr1h2–/– (n = 4), Nr1h3–/– 
Nr1h2–/– (n = 3), and WT (n = 3) mice with the histochemical stain oil red O (ORO) to evaluate the presence 
of  neutral lipids within the retina. Although the RPE and BrM of  WT mice were absent of  neutral lipids 
(Figure 6A), Nr1h3–/– mice displayed robust staining in sub-RPE deposits and within BrM (Figure 6B). 
Nr1h2–/– mice displayed a strong globular staining pattern within and below the RPE cell layer (Figure 6C). 
Nr1h3–/– Nr1h2–/– mice also displayed strong ORO-positive staining not only within the RPE cells but also 
in sub-RPE deposits (Figure 6D). ORO-positive staining in the tips of  the photoreceptor outer segments, as 
seen in the WT panel, served as a positive internal control (Figure 6A). Another characteristic of  sub-RPE 
deposits in AMD is the accumulation of  APOE, a regulator of  cholesterol transport, and oxidized lipopro-
teins (31, 32). Probing Nr1h3–/– (n = 4) and WT (n = 3) eyes with antibodies targeting APOE and oxidized 
phospholipids present in oxidized LDL (E06) revealed higher levels of  APOE and E06 immunoreactivity 
below the RPE in Nr1h3–/– (Figure 6F) compared with WT sections (Figure 6E), suggesting the buildup of  
oxidized lipids along the length of  BrM. QFDE imaging is a technique that allows for further interrogation 
of  lipoprotein particles in human aged BrM (33–36). En face visualization with QFDE displayed severely 
disrupted basal infoldings of  the RPE in Nr1h3–/– (Figure 6, I–K, and Supplemental Figure 13), compared 
with uniform and organized basal infoldings in WT mice (Figure 6, G and H). A different angle and depth 
of  fracture plane allowed us to examine the structure of  the RPE basement membrane, inner collagenous 
layer, and elastic layer of  BrM. Although the WT mice exhibited normal morphology, across BrM (Figure 
6L), select regions within BrM of  Nr1h3–/– mice presented with an accumulation of  fused, round particles 
(Figure 6M and Supplemental Figure 13D). A region of  the Nr1h3–/– BrM that lacked the accumulation of  
these spherical particles is also shown (Figure 6N). Given that the CC is also compromised in dry AMD, 
we visualized the ultrastructure of  the choriocapillary surface and found that in WT mice, fenestrations in 
the CC appeared as circular pores or “wagon wheels” (Supplemental Figure 14, A, B, E, and F). In Nr1h3–/– 
mice, fewer fenestrations were observed, and the “spokes” of  the fenestrations were fewer in the “wagon 
wheels” (Supplemental Figure 14, C, D, G, and H). These results provide a unique representation of  lipid 
deposition in regions below the RPE and details of  changes in RPE morphology associated with the loss 
of  Nr1h3. Finally, an evaluation of  RPE autofluorescence revealed a similar isoform-dependent pattern of  
severity, with significant upregulation seen in Nr1h3–/– (16.7%) and Nr1h3–/– Nr1h2–/– (20.0%) compared 
with the WT (Figure 6, O–S) mice and no significant changes seen in Nr1h2–/– RPE autofluorescence levels. 
These findings suggest that lipofuscin accumulation in the RPE cells, which may be a result of  dysregula-
tion of  lipid metabolism and clearance, as well as accumulation of  extracellular neutral lipid and apolipo-
protein are at least in part attributable to Nr1h3.
Nr1h3–/– mice exhibit a proinflammatory microenvironment in the outer retina. In addition to regulating genes 
involved in cholesterol transport, LXR is involved in regulation of  an array of  proinflammatory genes 
resulting from insults such as LPS, TNF-α, IL-1β, or bacterial stimulation (18), and it has been reported 
that LXR agonists may act as negative regulators of  macrophage inflammatory gene expression (37). Of  
relevance, recruitment of  immune cells to the outer retina is a purported feature of  the AMD etiology (38). 
We examined the outer retina of  Nr1h3–/– mice for inflammatory mediators. RPE-choroid flat mounts were 
prepared from aged WT (n = 5) and Nr1h3–/– (n = 8) mice, probed with a macrophage marker (ADGRE1, 
also known as F4/80), and stained with phalloidin to delineate the RPE cells. We observed a 3.8-fold accu-
mulation of  ADGRE1+ cells within the subretinal space of  Nr1h3–/– compared with WT mice (Figure 7, 
A–D), suggesting an augmented proinflammatory microenvironment in the subretinal space. However, we 
did not detect striking differences in the morphology of  phalloidin-stained RPE cell borders (Supplemental 
Figure 15, A–C). To further evaluate the cytokine milieu of  the outer retina, we examined the cytokine pro-
file of  the RPE-choroid tissue complex isolated from WT and Nr1h3–/– mice. Out of  a panel of  62 proteins, 
Nr1h3–/– samples exhibited a significant upregulation of  9 cytokines, with a primarily proinflammatory 
OCL, outer collagenous layer. (L) Representative image of healthy BrM from WT mouse, red dotted line; scale bar: 500 nm. (M) Representative image 
from Nr1h3–/– mouse, showing spherical particles in BrM, red dotted line and red arrowheads; scale bar: 500 nm. (N) A region of healthy BrM in the Nr1h3–/– 
mouse. Red dotted line; scale bar: 500 nm. Representative images of RPE autofluorescence from 10- to 14-month-old (O) WT, (P) Nr1h3–/–, (Q) Nr1h2–/–, 
and (R) Nr1h3–/– Nr1h2–/– mice. (S) Quantification of lipofuscin autofluorescence in RPE cells. n = 2 measurements in n = 5 eyes per genotype. Mean ± SEM 
shown. *P < 0.05, 1-way ANOVA, Dunnett’s multiple-comparisons test.
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profile (Figure 7, E and F). Interestingly, at a systemic level, 10 cytokines were found to be downregulated 
in the plasma of  Nr1h3–/– mice (Supplemental Figure 16, A and B). These results corroborate that Nrlh3 is 
involved in maintaining a homeostatic microenvironment in the outer retina.
Therapeutic targeting of  LXR diminishes pathogenic phenotypes associated with AMD. There is marked accumu-
lation of neutral lipids in the pentalaminar BrM in a normal eye with aging (39, 40). This lipid buildup in 
the posterior eye has been theorized to set the stage for the formation of extracellular lipid-rich deposits and 
specifically the development of drusen and basal deposits, phenotypic characteristics of early dry AMD (39, 
41, 42). Several studies have shown that this extracellular lipid deposition is, at least in part, due to the accu-
mulation of esterified cholesterol-rich APOB-containing lipoprotein particles (43, 44). Because mice predomi-
nantly produce the apoB48 protein, we used a mouse model that produces the full-length mouse apoB100 (23), 
as a proof of concept, to evaluate the therapeutic effect of modulating LXR activity. It is well established that 
the RPE-choroid of young apoB100 mice produces the apoB100 isoform and there is accumulation of neutral 
lipids in their BrM (24). Herein, 3-month-old apoB100 mice were fed a low-fat diet (LFD) or the LXR agonist 
GW3965, supplemented in a low-fat diet (LFD + GW), for 5 months. Mice in both groups displayed a similar 
rate of increase in weight with age, suggesting absence of any overt systemic toxicities (Supplemental Figure 
17A). We measured the expression of LXR target genes, Abca1 and Srebp1c, in RPE-choroid isolated from 
LFD- and LFD + GW–treated mice and found that their expression was upregulated in the LFD + GW cohort 
(Abca1: 54%, Srebp1c: 35%; n = 2), indicating that the drug was able to reach the posterior retina and activate 
LXR locally. Additionally, no differences were observed in the systemic levels of HDL and LDL/VLDL (Sup-
plemental Figure 17, B and C). Fundus and OCT imaging exhibited an improvement in the morphology of  
retinal layers as evident by a decrease in hypopigmented regions in fundus images of the LFD + GW group 
(Figure 8, C and D) as compared with LFD mice (Figure 8, A and B). We also observed a significant decrease 
in GFAP staining within the inner retina following activation of LXR in comparison with mice fed the LFD, 
supporting rescue of retinal injury associated with the apoB100 mice and a decline in inflammation (Figure 8, 
E and F). Quantification of the lipoprotein deposition in BrM of apoB100 mice revealed a significant decrease 
(77%) in the fraction of APOE+ length of BrM following LXR agonist treatment (Figure 8, G–I). GW3965 
treatment also led to a reduction in the number of ADGRE+ cells within the subretinal space (81%, P = 0.0598; 
Figure 8, J–L). Furthermore, examination of the ultrastructure of the retina/RPE/choroid complex from vehi-
cle-treated (LFD; Figure 8M) and drug-treated mice (LFD + GW) revealed disrupted RPE basal infoldings 
(Figure 8N) and intermittent thin sub-RPE deposits (Figure 8O) in the LFD cohort. These morphological 
Figure 7. Nr1h3–/– mice exhibit a proinflammatory microenvironment in the outer retina. RPE-choroid flat 
mounts from 10- to 14-month-old (A) WT and (B and C) Nr1h3–/–. Two examples are shown. ON, optic nerve. Mice 
were stained with ADGRE1 (green) and phalloidin (red). Scale bar: 50 μm. (D) Quantification of ADGRE1+ cells in 
RPE-choroid flat mounts from WT and Nr1h3–/– mice. WT, n = 5; Nr1h3–/–, n = 8. Mean ± SEM. *P < 0.01. Unpaired t 
test. (E) Protein isolated from RPE-choroid complexes of 10- to 14-month-old WT and Nr1h3–/– mice were blotted 
on a Mouse Cytokine Array C3 (62 proteins). Representative images of significantly regulated cytokines (2 dots/
protein) are shown. (F) Quantification of staining intensity of significantly regulated cytokines. n = 4 per group. 
Mean ± SEM shown. *P < 0.05; **P < 0.01; 2-tailed t tests.
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features displayed a marked improvement in the LFD + GW group (Figure 8, P–R). Finally, the LFD + GW 
group displayed distinct mitochondria (Supplemental Figure 18, C and D) relative to the vehicle group (Sup-
plemental Figure 18, A and B). These results signify that LXR activation is able to therapeutically influence 
inflammation and APOE deposition in the outer retina and may be a viable path for targeting these pathogenic 
pathways in AMD.
Discussion
The need to identify animal models that recapitulate early phenotypic features of  complex neurodegener-
ative diseases, such as dry AMD, is a necessity to serve as a platform to not only further understand the 
pathobiology of  disease but also facilitate testing of  potential therapies in preclinical studies. We hypoth-
esized that the LXR signaling pathway is likely an important mediator of  AMD pathobiology given its 
role as a regulator of  lipid metabolism, lipid transport, and inflammation, critical pathogenic pathways 
associated with disease development. To this end, we interrogated human ocular samples from donors with 
Figure 8. GW3965 diminishes pathogenic 
phenotypes associated with inflammation 
and lipid deposition. Fundus and OCT images 
of apoB100-expressing mice on control 
low-fat diet (LFD) diet (A and B) and LFD + 
GW3965 (GW) diet (C and D) after treatment. 
Black arrowheads point to hypopigmented 
regions in the fundus. GFAP staining in 
retina/RPE/choroid sections from LFD (E) 
and LFD + GW (F) mice. Representative 
images are shown. Scale bar: 50 μm. APOE 
immunolocalization in retina/RPE/choroid 
sections from LFD (G) and LFD + GW (H) mice. 
Representative images are shown. Scale bar: 
50 μm. (I) Quantification of APOE+ staining. n 
= 3 per group. Mean ± SEM shown. *P < 0.05, 
unpaired 2-tailed t test. ADGRE1+ staining 
in retina/RPE/choroid sections from LFD (J) 
and LFD + GW (K) mice. Ch, choroid; dotted 
line depicts Bruch’s membrane. Representa-
tive images are shown. Scale bar: 50 μm. (L) 
Quantification of subretinal ADGRE1+ cells. 
LFD, n = 3. Mean ± SEM shown. LFD + GW, n = 
4. Ns, not significant, unpaired 2-tailed t test. 
TEM images of the RPE cells from LFD-treat-
ed mice, showing (M) disrupted basal 
infoldings (red inset), (N) compromised RPE 
cells, and (O) sub-RPE deposits (red dotted 
line). (P–R) TEM images of the RPE cells from 
LFD + GW mice, showing improvement in RPE 
health, basal infoldings, and absence of sub-
RPE deposits. Scale bar: 2 μm (P).
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AMD for evidence of  LXR involvement and found that the expression of  LXR in human RPE cells, which 
are nurse cells to the retina and a primary vulnerable site in AMD, decreases as a function of  age. Further-
more, we found that drusen, the characteristic lesion of  early dry AMD, contain fragments that are LXR 
immunopositive. We demonstrated that the LXR signaling pathway can be activated in human RPE cells 
in vitro and characterized the ocular phenotype and function of  Nr1h3-, Nr1h2-, and Nr1h3 Nr1h2–knockout 
mice. Interestingly, we found an isoform-dependent ocular phenotype, with Nr1h3–/– mice demonstrating 
accumulation of  sub-RPE extracellular lipids, a distinguishing characteristic of  early dry AMD, while the 
pathology of  Nr1h2–/– mice mimicked RPE lipoidal degeneration. Preclinical studies allowed testing of  
the efficacy of  an LXR agonist, selected based on its ability to reestablish RPE cholesterol homeostasis 
and mitochondrial function, in an in vivo model with phenotypic features of  dry AMD. Collectively, our 
results have identified a potentially novel mouse model with characteristic features of  dry AMD, identified 
mechanisms of  LXR-based therapies, demonstrated efficacy of  targeting the LXR pathway, and supported 
developing LXR-directed therapies for the treatment of  neurodegenerative diseases of  aging, such as AMD, 
in which altered cellular metabolism and inflammation may play a role.
This study is the first comprehensive characterization of  the posterior ocular function and phenotype 
of  LXR-knockout mice to our knowledge. Though redundancies have been shown in the function of  the 
2 LXR isoforms in other organs, including the liver, isoform-specific functions have also been discovered. 
Systemically, aged, LXR-deficient mice have been shown to display isoform-specific differences in plas-
ma cholesterol levels, with absence of  Nr1h2 associated with significant elevation of  total cholesterol and 
HDL levels and absence of  either Nr1h3 or Nr1h2 associated with increased LDL levels (45). Additionally, 
Nr1h3–/– mice have been shown to display rapid accumulation of  large amounts of  cholesterol, leading to 
impaired hepatic function (46). Conversely, Nr1h2–/– mice maintain their resistance to dietary cholesterol, 
despite differences in the expression of  genes involved in lipid metabolism (47). Similarly, differences in 
expression of  target genes have been reported in the epididymis of  12-month-old mice, with the absence of  
the β-isoform but not α associated with a significant loss of  expression of  the cholesterol transporters, Abca1 
and Abcg1 (45). In our investigations, we found that the LXR pathway must also be critical for the devel-
opment of  normal visual function, because visual function deficits, mostly corresponding to the posterior 
region of  the eye and specifically the RPE, were detected. Importantly, decrease in the function of  RPE 
cells was observed primarily in mice deficient in Nr1h3. Furthermore, we found that both isoforms, along 
with their obligate binding partners, the RXRs, were expressed in several ocular tissues of  the posterior 
pole, including the retina, RPE, and choroid. Isoform-specific variations were also found in physiological 
and pathological processes under the control of  each of  the isoforms in the eye. Absence of  Nr1h2 affected 
the anterior segment, resulting in stellate cataract formation as well as accumulation of  intracellular and 
extracellular lipid deposits, while Nr1h3-null mice primarily developed RPE extracellular lipid accumula-
tion. When both isoforms were absent, not surprisingly, not only were all phenotypes evident, but also life 
expectancy was diminished with many mice perishing by 10–11 months of  age.
That the LXR signaling pathway may be important in the aging eye is not surprising, given the impor-
tance of  cholesterol regulation in the retinal milieu. The retina relies on both local synthesis as well 
as delivery from systemic circulation to replenish its cholesterol reserves (48, 49). Furthermore, it uses 
HDL-mediated reverse cholesterol transport and metabolism of  cholesterol to more soluble oxysterols for 
its elimination (49, 50). The excess cholesterol may remain in the retina and undergo oxidation because of  
exposure to light and endogenous free radicals (51, 52). Given the fact that LXRs, key regulators of  choles-
terol homeostasis, are expressed in retina and RPE and oxysterols act as endogenous ligands for LXRs, it 
is plausible that LXRs may be one of  the principal regulators of  lipid metabolism and transport in the eye. 
This was confirmed by our in vivo assessments, which show accumulation of  neutral and oxidized lipids 
below the RPE and within BrM, as evident by positive ORO and E06 staining in the absence of  Nr1h3. 
Accumulation of  oxidized lipids is an important contributor to AMD pathogenesis because these oxidized 
lipids can directly contribute to tissue injury or recruit inflammatory mediators in the outer retina (53). 
QFDE TEM is an imaging technique that has previously been used to visualize lipid particles, believed 
to be lipoproteins in human aged donor eyes (54). In conjunction with conventional TEM, we were able 
to study the topology and ultrastructure of  lipid deposits in detail in the RPE/BrM complex. Although 
normal and healthy RPE basal infoldings in the WT mice were seen, Nr1h3–/– mice displayed regions of  
severely disrupted basal infoldings amid healthy regions. The en face images of  RPE/BrM/CC complex 
from Nr1h3–/– mice acquired by this technique displayed “deposits” above the inner collagenous layer. 
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Of note, the Nr1h3–/– mice did not etch as well as the WT mice with QFDE, suggesting the presence of  
low volatiles, such as an abundance of  lipids. This corroborates the histological and IHC findings in our 
mouse model of  the presence of  neutral lipids, using ORO staining, and apolipoproteins within BrM and 
below the RPE, pathologies characteristic of  human AMD. This is the first demonstration to our knowl-
edge of  the pathology of  the posterior pole of  Nr1h3–/– mouse eye using QFDE and specifically visual-
ization of  disrupted basal infoldings and depots of  spherical/lipid-like particles. Collectively our imaging 
results show that loss of  Nr1h3 leads to accumulation of  lipids in the RPE/BrM complex, which may stem 
from dysregulation of  lipid clearance pathways in the eye.
Considerable evidence has emerged to indicate that the LXR pathway regulates inflammation and 
immune processes. In vivo, LXR-deficient mice have a sustained state of  heightened proinflammatory medi-
ators, with specifically Nr1h3–/– mice displaying exacerbated CCl4-induced lesions, in addition to inflamma-
tion and collagen deposition, in a model of  chronic liver injury (55). In a model of  retinal injury by N-meth-
yl-d-aspartate, LXR activation reduced retinal neurotoxicity of  the treatment and inhibited the increase of  
phospho-p38 MAPK and proinflammatory cytokine TNF-α in the treated mice (56). Additionally, activation 
of  the LXR pathway represses a set of  inflammatory genes, including Nos2, mt-Co2, Il6, and Il1b, after LPS, 
TNF-α, or IL-1β stimulation (37). In our study, we have shown the accumulation of  ADGRE1+ macro-
phages in the outer retina of  Nr1h3–/– mice, indicating a proinflammatory microenvironment. We also mea-
sured the cytokine profile of  the RPE-choroid complex and found a proinflammatory cytokine profile in 
Nr1h3–/– mice compared with the WT mice. This panel of  cytokines included IGFBP3, IGFBP5, IL12 P70, 
IL13, CCL9, CXCL2, SELP, CCL5, and LEPR. IGF axis gene polymorphisms have been associated with 
advanced AMD, and specifically IGFBP3 and IGFBP5 have been shown to be expressed in RPE progressive 
phenotypes, namely normal, early reactive, and myofibroblasts (57, 58). IL-13 levels have also been found to 
be upregulated in the aqueous humor of  patients diagnosed with neovascular AMD, suggesting a patholog-
ical role in AMD progression (59). CCL9 and CXCL2 have been reported to be involved in the recruitment 
of  neutrophils to the site of  injury and might act as a chemoattractant for the ADGRE1+ macrophages (60). 
Furthermore, CCR5 shows a trend to be elevated in a subset of  monocytes isolated from treatment-naive 
neovascular AMD patients (61). Interestingly, we observed that systemic levels of  cytokines significantly 
decreased in Nr1h3–/– mice compared with the controls, some with reported protective properties. CXCL1 
has been reported to confer a neuroprotective function in a model of  experimental autoimmune encepha-
lomyelitis (62). Colony stimulating factor 1 (CSF1) has been implicated in repair following acute kidney 
injury, suggesting that a decline in systemic CSF1 levels may have a detrimental effect on tissue homeostasis 
(63). The contrary trend seen in RPE-choroid and systemic levels of  IGFBP3, CCL9, and CXCL2, together 
with the ocular phenotype observed in knockout mice, implies that local cytokine milieu may have a more 
dominant role in maintaining homeostasis and/or contributing to disease, especially in an organ such as 
the eye, which enjoys immune privilege. Though it remains to be seen if  the inflammation observed in these 
mice is a direct consequence of  the absence of  LXR or if  it occurs in response to the elevated lipid accumu-
lation, we construe that loss of  Nr1h3 leads to a proinflammatory ocular environment, which may aid in the 
progression of  the disease by altering RPE and/or choroidal endothelial cells.
Finding and developing therapies for dry AMD has been a challenge to date. This dilemma is, in part, due 
to the complexity of this neurodegenerative disease, with multiple retinal cells affected and pathogenic pathways 
involved, raising the question of which cells and/or pathways should be targeted. One strategy has been to target 
genetic risk factors or modify environmental factors associated with disease progression. An alternative strategy 
would be to strengthen the armor of AMD-vulnerable cells and reinforce pathways that are compromised as 
a function of age. We found that expression of LXRs decreases as a function of age and, in particular, in the 
“elderly” risk age group, supporting the hypothesis that activating LXR may have beneficial effects on the overall 
health of RPE cells. Two factors must be considered in pursuing preclinical testing of an LXR-targeted therapy.
The first is the choice of  activating ligand. To date, several activating LXR ligands have been reported to 
modulate lipid metabolism and inflammatory pathways in different injury models, including the eye. Activat-
ing LXR with GW3965 has been shown to provide a protective effect in experimental diabetic retinopathy 
and an inner retinal damage mouse model (56, 64), and the LXR agonist TO901317 has been shown to 
ameliorate amyloid β–induced inflammatory responses in human RPE cells as well as the neural retina (65, 
66). It is important to note, however, that LXR ligands are not without side effects, most notably tempo-
rary hypertriglyceridemia. Furthermore, the TO901317 compound, the first LXR ligand to be identified and 
one that has been tested frequently by researchers, has potential off-target effects through activation of  other 
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nuclear receptors, including farnesoid X receptor and pregnane X receptor (67, 68). The selectivity of  LXR 
ligands can be attributed to several factors, including degree of  induction of  genes involved in lipid transport, 
namely, ABCA1, ABGA1, and APOE, or of  transrepression of  proinflammatory genes, such as nitric oxide 
synthase and cyclooxygenase-2, or proinflammatory cytokines in microglia and astrocytes (47, 69, 70). It has 
further been proposed, but unproved, that GW3965 and TO901317 may bind to both isoforms with varying 
degrees of  binding affinity (71). In our studies, in vitro assays allowed comparison of  the function of  agonists 
GW3965 and TO901317, versus the antagonist GSK2033 in RPE and choroidal endothelial cells. We found 
these activating ligands bind to both isoforms, NR1H3 and NR1H2, as evident by the induction of  promoter 
activity and target gene expression, in the presence of  siRNA targeting individual isoforms. Our in vitro, 
AMD-relevant endpoints for assessing LXR ligand efficacy included mitochondrial membrane potential, as a 
measure of  mitochondrial health, and lipid accumulation. The choice to assess the mitochondria was in light 
of  the extensive evidence supporting a contributory role of  mitochondrial dysfunction, changes in mitochon-
drial number and size, increased mitochondrial DNA damage, and a decline in DNA damage repair in AMD 
(72–75). Furthermore, the mitochondrial enzyme cytochrome P450 27A1 (CYP27A1) regulates cholesterol 
homeostasis, bile acid biosynthesis, activation of  vitamin D3, and removal of  the cytotoxic metabolite 7-keto-
cholesterol, and its absence in mice results in upregulation of  cholesterol biosynthesis in the mouse retina, 
along with sub-RPE accumulation (76, 77), supporting additional contributions of  mitochondrial function to 
AMD pathogenesis. We found that the ability of  LXR activation to prevent mitochondrial injury when RPE 
cells are exposed to multiple oxidative insults, including treatment with sodium iodate, hydrogen peroxide, 
CSE, and lipid overload, was selective and based on the type of  oxidant injury. TO901317 was effective in 
countering “classical” oxidant injury, such as NaIO3, H2O2, and CSE, whereas GW3965 was effective in ame-
liorating mitochondrial injury induced by lipid treatment. Similarly, we found that only GW3965 was able to 
prevent intracellular lipid accumulation in response to treatment with PA and α-LA in RPE cells.
The second factor to be considered for preclinical studies is the choice of  animal model. We tested the 
therapeutic effect of  LXR activation on lipid deposition and inflammation in the apoB100 mouse model, 
which is characterized by accumulation of  neutral lipids below the RPE (24), a phenotypic feature of  aging 
and potential precursor to development of  AMD. Furthermore, in these mice, the cholesterol transporter, 
apoE, also accumulates below the RPE in the space where sub-RPE deposits develop (32). We chose to 
deliver the drug via diet because systemic delivery of  LXR ligands has been used to target the brain and 
both GW3965 and TO901317 have been shown to pass the blood-brain barrier (78, 79). We observed that 
apoB100 mice fed a diet rich in GW3965 for 5 months displayed a decline in expression of  inflammatory 
markers (GFAP and ADGRE1) within the retina and apoE deposition within BrM, supporting the thera-
peutic potential of  activating LXR to target these AMD-associated pathologies.
Several studies to date have examined the phenotype of  tissue-specific knockdown of  downstream tar-
get genes of  the LXR, including ABCA1 in photoreceptor and RPE cells (80, 81). In the absence of  Abca1 
in mouse photoreceptors, there is accumulation of  neutral lipid-rich subretinal debris and Aif1+ subretinal 
cells, along with compromise in visual function (81) while the absence of  Abca1 in the mouse RPE demon-
strated retinal degenerative changes, including significant RPE and retinal degeneration concomitant with 
RPE lipoidal degeneration, a phenotype also seen in our Nr1h2–/– mice (80). Given previous findings that 
Abca1 levels are affected more so in the absence of  the β-isoform than α-isoform, it is plausible that down-
stream effectors other than Abca1 may be involved in the accumulation of  lipids extracellular to RPE cells 
(e.g., the lipid-rich drusen phenotype). Additionally, phenotypic characterization of  Nr1h2–/– mice, which 
exhibit inflammation of  the optic nerve and loss of  ganglion cells with aging, suggests that the β-isoform is 
a major contributor to the regulation of  inflammation in the inner retina (82). Ban et al. targeted the lipid 
efflux pathway in macrophages by deleting Abca1 and Abcg1 and found that the double-knockout mice 
present with extracellular lipid-rich deposits in the outer retina, below the retina, concomitant with photo-
receptor dysfunction (83). Collectively, these reports in conjunction with our results support that both LXR 
isoforms are involved in the regulation of  inflammation and lipid deposition in the inner and outer retina, 
but in an isoform-specific manner, and support the need for future studies examining the impact of  LXR 
using tissue-specific knockout models.
Overall, our study establishes the LXR pathway as a key regulator of  lipid transport and inflammation 
in the eye. Aged mice lacking the α-isoform represent a new mouse model of  the dry AMD phenotype and 
may be used as a platform to test therapies specifically targeting excess extracellular lipid accumulation 
and inflammation. Further, we identified mechanisms of  LXR-based therapies and demonstrated in vivo 
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efficacy of  targeting the LXR pathway. Importantly, our results underscore the importance of  the health 
of  RPE cells, located at an important interface to regulate delivery of  cholesterol to the retina as well as 
its elimination, highlighting their importance as a target for ocular pathologies governed by excessive lipid 
accumulation in the posterior pole (84). Broadly, this translational study supports developing LXR-targeted 
therapies for the treatment of  neurodegenerative diseases of  aging, in which altered cellular metabolism 
and chronic inflammation may play a role.
Methods
Human tissue and cell lines. Use of  human donor eyes for research was approved by the Duke University 
Institutional Review Board. Details of  methods associated with tissue collection and cell culturing are 
provided in the supplemental materials.
Animals. Male and female Nr1h3 Nr1h2+/+ (WT), Nr1h3–/–, Nr1h2–/–, and Nr1h3–/– Nr1h2–/– mice 
on the C57BL/6J background were used to examine the effect of  the absence of  Nr1h2 and Nr1h3 in 
vivo. Mice that express apoB100 (apoB100 mice, genetic background: 50% C57BL/6 and 50% 129/Sv) 
(24) were used to evaluate the effect of  an LXR agonist in vivo. Additional details are provided in the 
supplemental materials.
Supplemental methods. Additional details of  methods, including RNA isolation, quantitative PCR, siR-
NA transfection, transcriptional activity, AdipoRed, cell viability assays, JC-1 assay, blood collection, cyto-
kine array, and postmortem tissue analyses, are provided in the Supplemental Methods and Supplemental 
Table 5.
Statistics. Statistical methods for data analysis included 2-tailed t test and 2-way ANOVA, with Tukey’s/
Dunnett’s (as recommended by GraphPad Prism) multiple-comparisons test using GraphPad Prism. Values 
were considered statistically significant at P < 0.05 and are indicated in the figures. For in vitro experiments, 
including transcriptional activity assays, JC-1, AdipoRed, and cell viability, samples were run in triplicate, 
and experiments were performed a minimum of  3 times (technical and biological replicates = 3).
Study approval. The study protocols were approved by the Duke University Institutional Animal 
Care and Use Committees, and all animal experiments were performed in accordance with the guide-
lines of  the Association for Research in Vision and Ophthalmology Statement for the Use of  Animals 
in Ophthalmic and Vision Research.
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